Cost-effectiveness analysis comparing “PARP inhibitors-for-all” to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer

OBJECTIVES. Clinical trials evaluating universal PARP inhibitor (PARPi) frontline maintenance therapy for advanced stage ovarian cancer have reported progression-free survival (PFS) benefit. It is unclear whether PARPi maintenance therapy will universally enhance value (clinical benefits relative to...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Gynecol Oncol
Auteurs principaux: Gonzalez, Rafael, Havrilesky, Laura J., Myers, Evan R., Secord, Angeles Alvarez, Dottino, Joseph A., Berchuck, Andrew, Moss, Haley A.
Format: Artigo
Langue:Inglês
Publié: 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8086124/
https://ncbi.nlm.nih.gov/pubmed/32863036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2020.08.003
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires